Who Exports Fenofibrate from India — 168 Suppliers Behind a $73.4M Market
India's fenofibrate export market is supplied by 168 active exporters who collectively shipped $73.4M across 2,794 shipments. ABBOTT HEALTHCARE PRIVATE LIMITED leads with a 14.5% market share, followed by HETERO LABS LIMITED and CIPLA LIMITED. The top 5 suppliers together control 53.3% of total export value, reflecting a moderately competitive market structure.
Top Fenofibrate Exporters from India — Ranked by Export Value
ABBOTT HEALTHCARE PRIVATE LIMITED is the leading fenofibrate exporter from India, holding a 14.5% share of the $73.4M market across 2,794 shipments from 168 exporters. The top 5 suppliers — ABBOTT HEALTHCARE PRIVATE LIMITED, HETERO LABS LIMITED, CIPLA LIMITED, SUN PHARMACEUTICAL INDUSTRIES LIMITED, ATHENA DRUG DELIVERY SOLUTIONS PRIVATE LIMITED — collectively control 53.3% of total export value, indicating a moderately concentrated market. Individual shares are: ABBOTT HEALTHCARE PRIVATE LIMITED (14.5%), HETERO LABS LIMITED (11.3%), CIPLA LIMITED (9.7%), SUN PHARMACEUTICAL INDUSTRIES LIMITED (9.6%), ATHENA DRUG DELIVERY SOLUTIONS PRIVATE LIMITED (8.2%).
Top Fenofibrate Exporters from India
Ranked by export value · 168 active suppliers · Indian Customs (DGFT) data
| # | Supplier & Formulations | Value | Ctry. | Share |
|---|---|---|---|---|
| 1 | ABBOTT HEALTHCARE PRIVATE LIMITED FENOCOL 145 MG TABLETFENOFIBRATE TAB 145MGFENOFIBRATE TABLET | $10.6M | 5 | 14.5% |
| 2 | HETERO LABS LIMITED FENOFIBRATE TABLETFENOCOL 145 MG TABLETFENOFIBRATE 145MG TABLET | $8.3M | 8 | 11.3% |
| 3 | CIPLA LIMITED FENOFIBRATE TABLETFENOCOL 145 MG TABLETFENOFIBRATE 145MG TABLET | $7.1M | 3 | 9.7% |
| 4 | SUN PHARMACEUTICAL INDUSTRIES LIMITED FENOFIBRATE CAPSULES 200MG PACK :4X7S BAFENOCOL 145 MG TABLETFENOFIBRATE TABLET | $7.0M | 10 | 9.6% |
| 5 | ATHENA DRUG DELIVERY SOLUTIONS PRIVATE LIMITED FENOFIBRATE PELLETS CAS NO. 49562-28-9FENOFIBRATE PELLETSROSUFEN 10/160[52350PACKX3X10=1570500 TABS] | $6.0M | 12 | 8.2% |
| 6 | AJANTA PHARMA LIMITED FENOFIBRATE TABLETFENOFIBRATE 145MG TABLETFENOFIBRATE CAPSULES USP 134 MG | $4.7M | 3 | 6.4% |
| 7 | MANKIND PHARMA LIMITED FENOFIBRATE TABLETFENOFIBRATE 145MG TABLETFENOFIBRATE CAPSULES USP 134 MG | $4.2M | 1 | 5.7% |
| 8 | MYLAN LABORATORIES LIMITED FENOFIBRATE TABLETFENOCOL 145 MG TABLETFENOFIBRATE 145MG TABLET | $3.5M | 3 | 4.8% |
| 9 | AMNEAL PHARMACEUTICALS PRIVATE LIMITED FENOFIBRATE TABLETFENOFIBRATE 145MG TABLETFENOFIBRATE CAPSULES USP 134 MG | $3.5M | 1 | 4.7% |
| 10 | ABBOTT HEALTH CARE PRIVATE LIMITED FENOCOL 145 MG TABLETFENOFIBRATE TAB 145MGFENOFIBRATE TABLET | $2.0M | 2 | 2.7% |
| 11 | ALEMBIC PHARMACEUTICALS LIMITED FENOFIBRATE TABLETFENOFIBRATE 145MG TABLETFENOFIBRATE CAPSULES USP 134 MG | $1.5M | 1 | 2.0% |
| 12 | INVENTIA HEALTHCARE LIMITED FENOFIBRATE TABLETFENOFIBRATE 145MG TABLETFENOFIBRATE CAPSULES USP 134 MG | $1.4M | 4 | 2.0% |
| 13 | V-ENSURE PHARMA TECHNOLOGIES PRIVATE LIMITED FENOFIBRATE TABLETFENOFIBRATE 145MG TABLETFENOFIBRATE CAPSULES USP 134 MG | $1.4M | 1 | 1.9% |
| 14 | TORRENT PHARMACEUTICALS LTD FENOFIBRATE TABLETFENOFIBRATE 145MG TABLETFENOFIBRATE CAPSULES USP 134 MG | $1.4M | 5 | 1.9% |
| 15 | LUPIN LIMITED FENOFIBRATE TABLETFENOFIBRATE 145MG TABLETFENOFIBRATE CAPSULES USP 134 MG | $1.0M | 1 | 1.4% |
Related Analysis
Supplier Certification & Compliance Matrix
FDA, WHO-GMP, and EU GMP status for top Fenofibrate exporters
| Supplier | US FDA | WHO-GMP | EU GMP | ANDAs | Notes |
|---|---|---|---|---|---|
| Alembic Pharmaceuticals Limited | Approved | Yes (July 2025) | Yes | Multiple | Received multiple FDA approvals between 2024 and 2025; WHO-GMP certified in July |
| Ajanta Pharma Limited | Approved | Yes (December 2023) | Yes | Multiple | WHO-GMP certified in December 2023; holds multiple FDA approvals. (extranet.who. |
| Cipla Limited | Approved | Yes | Yes | Multiple | WHO-GMP certified; holds multiple FDA approvals. |
| Hetero Labs Limited | Approved | Yes | Yes | Multiple | WHO-GMP certified; holds multiple FDA approvals. |
| Lupin Limited | Approved | Yes | Yes | Multiple | WHO-GMP certified; holds multiple FDA approvals. |
| Mylan Laboratories Limited | Approved | Yes | Yes | Multiple | WHO-GMP certified; holds multiple FDA approvals. |
| Sun Pharmaceutical Industries Limited | Approved | Yes | Yes | Multiple | WHO-GMP certified; holds multiple FDA approvals. |
| Abbott Healthcare Private Limited | Approved | Unknown | Yes | Multiple | EU-GMP certified; holds multiple FDA approvals. (cms.mhra.gov.uk) |
| Alembic Pharmaceuticals Limited | Approved | Yes (July 2025) | Yes | Multiple | Received multiple FDA approvals between 2024 and 2025; WHO-GMP certified in July |
TransData Nexus reviewed the regulatory standing of 9 leading Fenofibrate exporters from India. 9 hold US FDA facility approvals, 8 maintain WHO-GMP certification, and 9 are EU GMP compliant. For regulated markets (US, EU, Australia), prioritise suppliers with active FDA or EU GMP approvals. For semi-regulated markets (Africa, ASEAN, Latin America), WHO-GMP certification is the minimum recommended standard.
Certification status compiled from publicly available regulatory databases including FDA Orange Book, WHO Prequalification database, and EMA GMP registry. Buyers should independently verify compliance status with the relevant regulatory authority before placing orders.
TransData Nexus Research · Mar 2026
Manufacturing Hub Analysis — Vendor Proximity
India's pharmaceutical clusters relevant to Fenofibrate sourcing
1Hyderabad — Bulk Drug Capital
Hyderabad, often referred to as the "Bulk Drug Capital of India," is a major hub for the production of Active Pharmaceutical Ingredients (APIs). The city hosts over 800 pharmaceutical companies, including industry leaders such as Dr. Reddy's Laboratories and Aurobindo Pharma. The presence of Genome Valley, India's first biotech cluster, underscores Hyderabad's commitment to pharmaceutical innovation and research. This concentration of expertise and infrastructure makes Hyderabad a critical player in the manufacturing of APIs like fenofibrate.
2Ahmedabad-Vadodara — Formulations Hub
The Ahmedabad-Vadodara corridor in Gujarat is renowned for its focus on pharmaceutical formulations. Gujarat contributes nearly 28% of India's pharmaceutical production, with major companies such as Zydus Cadila and Torrent Pharmaceuticals operating in the region. The state's robust support infrastructure, including well-developed ports and transportation networks, facilitates efficient production and distribution of pharmaceutical products, including fenofibrate formulations.
3Mumbai-Thane-Raigad — Export Gateway
The Mumbai-Thane-Raigad belt serves as a significant export gateway for India's pharmaceutical industry. Mumbai, being a major commercial hub, hosts numerous pharmaceutical companies and provides access to international markets through its ports. This region's strategic location and established infrastructure make it a key area for the export of pharmaceuticals, including fenofibrate, to destinations such as the United States, Belgium, and Australia.
4Baddi-Nalagarh — Tax Incentive Zone
Baddi, located in Himachal Pradesh, is recognized as Asia's largest pharmaceutical hub. The region's growth has been significantly influenced by favorable government policies, including tax incentives that have attracted numerous pharmaceutical companies. Baddi's strategic location and well-developed infrastructure contribute to its prominence in pharmaceutical manufacturing.
5Sourcing Recommendations
- Diversify Supplier Base: Engage with multiple suppliers across different clusters to mitigate risks associated with regional disruptions.
- Evaluate Supplier Capabilities: Assess the manufacturing capabilities and regulatory compliance of suppliers in Hyderabad for API production and in Ahmedabad-Vadodara for formulations.
- Leverage Export Infrastructure: Utilize the export facilities in the Mumbai-Thane-Raigad region to streamline international distribution of fenofibrate products.
- Consider Cost Advantages: Explore opportunities in Baddi-Nalagarh to benefit from tax incentives and cost-effective manufacturing solutions.
By strategically sourcing from these diverse pharmaceutical clusters, TransData Nexus can optimize its supply chain for fenofibrate, ensuring reliability, compliance, and cost efficiency.
Recent M&A, Collaborations & Capacity Expansions
Industry developments among top Fenofibrate exporters from India
Sun Pharmaceutical Industries Limited — Sun Pharma acquires remaining stake in Taro Pharmaceuticals
Sun Pharma entered into a definitive merger agreement to acquire the remaining stake in Taro Pharmaceuticals for $347.73 million. - IMPACT: This acquisition is expected to enhance Sun Pharma's global market presence, potentially increasing its Fenofibrate export capabilities.
Impact: This acquisition is expected to enhance Sun Pharma's global market presence, potentially increasing its Fenofibrate export capabilities.
Common Questions — Fenofibrate Suppliers from India
Answers based on Indian Customs (DGFT) shipment records compiled by TransData Nexus
Q Which fenofibrate supplier from India is the most reliable for bulk orders?
Based on shipment frequency and export consistency, ABBOTT HEALTHCARE PRIVATE LIMITED leads with 50 recorded shipments worth $10.6M. HETERO LABS LIMITED (338 shipments) and CIPLA LIMITED (329 shipments) are also established high-volume exporters.
Q How many fenofibrate manufacturers are there in India?
India has 168 active fenofibrate exporters with a combined export market of $73.4M across 2,794 shipments to 81 countries. The top 5 suppliers hold 53.3% of total export value.
Q What certifications should I verify?
Verify: WHO-GMP certification (most markets), US FDA approval (United States), EU GMP certificate (EU/EEA), and Free Sale Certificate from CDSCO. Always request a Certificate of Analysis (CoA) and Certificate of Origin (CoO).
Q What is the typical price range for fenofibrate from India?
Average FOB unit price: $8.19 per unit, ranging from $0.00 to $749.73. Average shipment value: $26.3K.
Official References & Regulatory Resources
- CDSCO India
- Pharmexcil
- IBEF — India Pharma Industry
- Ministry of Commerce — Pharma Exports
- India Trade Statistics (DGFT)
Verify manufacturer licensing and export certifications with the official agencies above.
Research Methodology & Data Transparency
Suresh Sormare
Verified AuthorPharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormarePrimary Data Source
All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Analysis Methodology
- 1.Supplier Ranking: 168 verified Indian exporters of Fenofibrate ranked by capped export value from DGFT shipping bill records.
- 2.Export Value Analysis: Total export value aggregated from 2,794 individual shipping bill records. Values are FOB in USD.
- 3.Statistical Normalization: Shipment values are statistically normalized to ensure accurate market share representation.
- 4.Market Concentration: Supplier market share and geographic reach analyzed across 81 destination countries.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
2,794 Verified Shipments
168 exporters tracked
Expert-Reviewed
By pharmaceutical trade specialists